Coast Investment & Development Company K.S.C.P. (KWSE:COAST)

Ligand Pharmaceuticals Income Statement

Financials in millions KWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	0.18	0.2	0.28	0.56	0.6	0.59
Other Revenue	1.74	1.56	3.49	3.02	4.84	-3.31
Revenue	1.93	1.75	3.77	3.58	5.44	-2.72
Revenue Growth (YoY)	-47.99%	-53.52%	5.30%	-34.20%	-	-
Gross Profit	1.93	1.75	3.77	3.58	5.44	-2.72
Selling, General & Admin	1.14	1.23	1.37	1.35	1.34	1.1
Other Operating Expenses	0.01	0.01	0.01	0.03	0.1	-
Operating Expenses	1.17	1.26	1.39	1.39	1.46	1.12
Operating Income	0.76	0.5	2.38	2.19	3.98	-3.84
Currency Exchange Gain (Loss)	0.1	-0.06	0.07	-0.08	-0.15	0.19
Other Non Operating Income (Expenses)	-	-	-	-0.02	-0.03	-0.25
EBT Excluding Unusual Items	0.86	0.44	2.45	2.09	3.8	-3.9
Gain (Loss) on Sale of Investments	-	-	-	-	-	-6.29
Gain (Loss) on Sale of Assets	-	-	-	0.47	0.16	-
Other Unusual Items	-0	-0	0.19	-	-	-
Pretax Income	0.86	0.44	2.64	2.57	3.96	-10.19
Income Tax Expense	0	0	-	-	0.04	-
Earnings From Continuing Operations	0.86	0.44	2.64	2.57	3.92	-10.19
Net Income to Company	0.86	0.44	2.64	2.57	3.92	-10.19
Net Income	0.86	0.44	2.64	2.57	3.92	-10.19
Net Income to Common	0.86	0.44	2.64	2.57	3.92	-10.19
Net Income Growth	-64.17%	-83.45%	2.85%	-34.52%	-	-
Shares Outstanding (Basic)	465	465	465	465	465	465
Shares Outstanding (Diluted)	465	465	465	465	465	465
Shares Change (YoY)	-	-	-	-	-	6.98%
EPS (Basic)	0.00	0.00	0.01	0.01	0.01	-0.02
EPS (Diluted)	0.00	0.00	0.01	0.01	0.01	-0.02
EPS Growth	-64.18%	-83.46%	2.84%	-34.52%	-	-
Free Cash Flow	0.16	-0.46	1.68	0.83	-0.7	-0.31
Free Cash Flow Per Share	-	-0.00	0.00	0.00	-0.00	-0.00
Dividend Per Share	-	-	0.005	0.005	0.005	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	39.55%	28.42%	63.06%	61.11%	73.17%	-
Profit Margin	44.40%	24.92%	69.98%	71.65%	72.00%	-
Free Cash Flow Margin	8.26%	-26.31%	44.43%	23.16%	-12.93%	-
EBITDA	0.78	0.51	2.39	2.2	4	-3.82
EBITDA Margin	40.35%	29.00%	63.35%	61.41%	73.47%	-
D&A For EBITDA	0.02	0.01	0.01	0.01	0.02	0.02
EBIT	0.76	0.5	2.38	2.19	3.98	-3.84
EBIT Margin	39.55%	28.42%	63.06%	61.11%	73.17%	-
Effective Tax Rate	0.15%	0.29%	-	-	0.93%	-
Revenue as Reported	2.02	1.69	4.05	3.98	-	-2.53

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.